drugset / Trial / NCT06215859
Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
MR-107A-02 is being studied to investigate its efficacy and safety for treatment of acute pain after herniorrhaphy.
Timeline
- Start
- 2023-12-29
- Primary completion
- 2025-01-31
- Completion
- 2025-03-12
Outcome
Met primary endpoint
release “herniorrhaphy: LS mean difference in SPID 0-48h between MR-107A-02 and placebo = 50.1 (95% CI: 35.4, 64.8; p< 0.001)” viatris.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MR-107A-02 | Unknown | 15 mg | — |
| Comparator | Tramadol | Other / unclassified | 50 mg | — |
Indications
No indication recorded.